Eisai to present latest Lecanemab findings at AD/PD 2025

Eisai Co., Ltd. announced the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI^®), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer’s disease (AD), at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™) from April 1-5 in Vienna, Austria, and online. The lecanemab data and additional research findings from Eisai’s AD portfolio will be featured in 16 presentations, including 6 oral presentations.

Oral and Poster Presentations

Eisai will present three oral presentations and one poster presentation on lecanemab, among other results. These presentations will include the latest findings from real-world clinical evidence of lecanemab in the United States, efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) heterozygous carriers and non-carriers in the Phase III Clarity AD clinical study, and a subgroup analysis of Clarity AD open label extension study in the Asian region. In addition to the presentations, the clinical study design of a Phase II study of the anti-MTBR tau antibody E2814 in combination with lecanemab in people living with sporadic early AD, and research results to predict future brain tau accumulation using the ratio of phosphorylated tau 217 to non-phosphorylated tau 217 (pTau217 ratio) in plasma will be presented.

Eisai Symposium – Bridging the Gap in Alzheimer’s Disease: From Pathophysiology to Treatment Strategy  

Eisai is sponsoring a symposium featuring three leading global experts in the field of AD, on the topics of the pathophysiology of AD, treatment advancements and clinical implications for targeting AD pathology. The symposium aims to enhance understanding by providing expert insights into the key drivers and mechanisms of AD pathophysiology and neurodegeneration, the rationale for targeted approaches to anti-amyloid-β therapies, lessons from past drug development, and emerging treatment strategies.

Eisai Symposium – Transforming Outcomes in Early AD: A Focus on Intervention and Management

Eisai is sponsoring a symposium featuring prominent clinical experts in the field of AD. The symposium will provide updates and insights into early AD treatment from various perspectives, as well as information on future treatment directions.

View AD/PD 2025 Presentations Relating to Eisai’s Key Compounds and Research HERE.